Table 1.The pathologic distribution of rare and uncommon HPV types, excluding group 1-coinfection
Group |
Genotype |
Pathologic diagnosis (%)
|
Total (%) |
WNL |
LSIL |
HSIL |
SCC |
ADC |
ASC |
2A |
68 |
15 (46.9) |
5 (15.6) |
9 (28.1) |
3 (9.4) |
0 (0) |
0 (0) |
32 (7.2) |
2B |
26 |
1 (100.0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
1 (0.2) |
|
34 |
1 (100.0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
1 (0.2) |
|
53 |
50 (56.2) |
26 (29.2) |
12 (13.5) |
1 (1.1) |
0 (0) |
0 (0) |
89 (19.9) |
|
66 |
26 (60.5) |
14 (32.6) |
2 (4.7) |
1 (2.3) |
0 (0) |
0 (0) |
43 (9.6) |
|
69 |
0 (0) |
1 (100.0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
1 (0.2) |
|
70 |
66 (63.5) |
31 (21.8) |
4 (3.9) |
2 (1.9) |
1 (1.0) |
0 (0) |
104 (23.3) |
|
73 |
3 (75.0) |
1 (25.0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
4 (0.9) |
Unclassified |
32 |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
|
40 |
15 (57.7) |
8 (30.8) |
3 (11.5) |
0 (0) |
0 (0) |
0 (0) |
26 (5.8) |
|
42 |
4 (50.0) |
3 (37.5) |
1 (12.5) |
0 (0) |
0 (0) |
0 (0) |
8 (1.8) |
|
43 |
5 (62.5) |
2 (25.0) |
1 (12.5) |
0 (0) |
0 (0) |
0 (0) |
8 (1.8) |
|
44 |
2 (50.0) |
2 (50.0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
4 (0.9) |
|
54 |
30 (61.2) |
13 (26.5) |
2 (4.1) |
2 (4.1) |
2 (4.1) |
0 (0) |
49 (11.0) |
|
55 |
3 (75.0) |
0 (0) |
1 (25.0) |
0 (0) |
0 (0) |
0 (0) |
4 (0.9) |
|
57 |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
|
61 |
15 (78.9) |
4 (21.1) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
19 (4.3) |
|
62 |
0 (0) |
2 (100.0) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
2 (0.4) |
3 |
6 |
33 (84.6) |
3 (7.7) |
3 (7.7) |
0 (0) |
0 (0) |
0 (0) |
39 (8.7) |
|
11 |
11 (84.6) |
2 (15.4) |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
13 (2.9) |
Total |
|
259 (64.1) |
101 (25) |
33 (8.2) |
8 (2.0) |
3 (0.7) |
0 (0) |
447a [404]b (100) |
Table 2.The relationship between pathologic diagnoses and group 2 and unclassified HPV, compared to HPV16, HPV6, and 11 without group 1-coinfection
|
WNL vs LSIL, HSIL, IC
|
WNL, LSIL vs HSIL, IC
|
|
RR (95% CI) |
p-value |
RR (95% CI) |
p-value |
Group 2, unclassified |
1 |
< .001 |
1 |
< .001 |
HPV16 |
1.397 (1.222-1.598) |
|
3.191 (2.407-4.232) |
|
Group 2, unclassified |
2.616 (1.368-5.005) |
< .001 |
2.037 (0.657-6.310) |
.19 |
HPV6, 11a
|
1 |
1 |
|
|
Table 3.The relationship of abnormal findings in the evaluation of rare and uncommon HPV genotypes compared to HPV6 and 11 without group 1-coinfection
Genotypea
|
Abnormal findings (LSIL, HSIL, IC)
|
|
RR (95% CI) |
p-value |
68 |
HPV68 |
3.453 (1.688-7.064) |
< .001 |
|
HPV6, 11b
|
1 |
|
53 |
HPV53 |
2.848 (1.444-5.619) |
.001 |
|
HPV6, 11b
|
1 |
|
40 |
HPV40 |
2.750 (1.261-5.997) |
.01 |
|
HPV6, 11b
|
1 |
|
66 |
HPV66 |
2.570 (1.230-5.369) |
.01 |
|
HPV6, 11b
|
1 |
|
54 |
HPV54 |
2.520 (1.217-5.220) |
.01 |
|
HPV6, 11b
|
1 |
|
70 |
HPV70 |
2.375 (1.196-4.716) |
.01 |
|
HPV6, 11b
|
1 |
|
Table 4.The relationship of abnormal findings in the evaluation of rare and uncommon HPV genotypes compared to HPV16 without group 1-coinfection
Genotypea
|
Abnormal findings (LSIL, HSIL, IC)
|
|
RR (95% CI) |
p-value |
68 |
HPV16 |
1.059 (0.761-1.474) |
.73 |
|
HPV68 |
1 |
|
53 |
HPV16 |
1.284 (1.007-1.636) |
.03 |
|
HPV53 |
1 |
|
40 |
HPV16 |
1.330 (0.845-2.091) |
.16 |
|
HPV40 |
1 |
|
66 |
HPV16 |
1.423 (0.978-2.069) |
.03 |
|
HPV66 |
1 |
|
54 |
HPV16 |
1.451 (1.015-2.073) |
.02 |
|
HPV54 |
1 |
|
70 |
HPV16 |
1.539 (1.187-1.997) |
< .001 |
|
HPV70 |
1 |
|